Finance

Lists
Q3 2026 earnings • released • EPS beat +50.61% • Revenue beat +1.98%
See results
TARS:NASDAQ
Tarsus Pharmaceuticals Inc
$68.60
+1.60%
(+1.08) 1D
$70.00
+2.04% (+1.40)
After hours
Closed: Nov 6, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TARS...
Open
$67.78
High
$69.04
Low
$66.53
Mkt. cap
3.38B
Avg. vol.
1.01M
Volume
1.09M
52-wk high
$91.53
52-wk low
$53.89
EPS
-$15.18
Beta
0.34
Shares outstanding
49.31M
No. of employees
370
Open
$67.78
High
$69.04
Low
$66.53
Mkt. cap
3.38B
Avg. vol.
1.01M
Volume
1.09M
52-wk high
$91.53
52-wk low
$53.89
EPS
-$15.18
Beta
0.34
Shares outstanding
49.31M
No. of employees
370
News stories
From web sources and news partners
About Tarsus Pharmaceuticals Inc
CEO-
Employees370
Founded2016
HeadquartersIrvine, California, United States
SectorHealth Care
IndustryPharmaceutical industry
Websitetarsusrx.com
Analyst ratings
Based on 10 analysts giving stock ratings to TARS in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for TARS in the last 3 months.
Highest
Current $68.60
$116.00 (+69.10%)
Average
$105.38 (+53.62%)
Lowest
$97.00 (+41.40%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$102.00
+48.7%
11/06/2026
Eddie Hickman
Guggenheim
Buy
Reiterated
$97.00
+41.4%
11/04/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
11/04/2026
Mazahir Alimohamed
Oppenheimer
Buy
Maintained
$103.00
+50.1%
11/04/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$106.00
+54.5%
11/04/2026
Jenna Davidner
Barclays
Buy
Reiterated
$110.00
+60.3%
10/09/2026
Andrea Newkirk
Goldman Sachs
Buy
Initiated
$116.00
+69.1%
09/24/2026
Dennis Ding
Jefferies
Buy
Reiterated
$105.00
+53.1%
09/08/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/12/2026
Francois Brisebois
LifeSci Capital
Buy
Reiterated
$104.00
+51.6%
08/08/2026
Andreas Argyrides
Chardan Capital
Buy
Maintained
$98.00
+42.9%
04/24/2026
Last report
Nov 3, 2026
Fiscal period
Q3 2026
-$0.87 / -$1.77
+50.61%beat
Revenue / Est. (USD)
194.57M / 190.80M
+1.98%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
151.67M
162.05M
173.91M
194.57M
Cost of goods sold
28.96M
31.75M
12.11M
13.89M
Cost of revenue
28.96M
31.75M
12.11M
13.89M
Research and development expenses
-
-
31.01M
44.19M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
130.68M
136.43M
150.70M
168.02M
Operating expense
130.68M
136.43M
181.71M
212.21M
Total operating expenses
159.64M
168.18M
193.82M
226.11M
Operating income
-7.98M
-6.12M
-19.91M
-31.54M
Other non operating income
4.48M
-936.00K
-281.00K
91.00K
EBT including unusual items
-6.31M
-4.62M
-15.84M
-663.69M
EBT excluding unusual items
-1.76M
-5.46M
-18.65M
-29.86M
Income tax expense
2.06M
2.35M
2.72M
4.64M
Effective tax rate
-32.61%
-50.96%
-17.15%
-0.70%
Other operating expenses
-
-
-
-
Net income
-8.37M
-6.97M
-18.55M
-668.33M
Net profit margin
-5.52%
-4.30%
-10.67%
-343.49%
Earnings per share
-0.20
-0.16
-0.43
-0.87
Interest and investment income
3.95M
3.72M
3.70M
3.78M
Interest expense
-2.21M
-2.13M
-2.16M
-2.18M
Net interest expenses
1.74M
1.59M
1.54M
1.59M
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.53M
-5.68M
-18.91M
-30.51M
Gain or loss from assets sale
-
-
183.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps